Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control

S. Akalin; K. Berntorp; A. Ceriello; A. K. Das; E. S. Kilpatrick; T. Koblik; C. S. Munichoodappa; C. Y. Pan; W. Rosenthall; M. Shestakova; B. Wolnik; V. Woo; W. Y. Yang; M. T. Yilmaz

doi:10.1111/j.1742-1241.2009.02165.x

Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control

S. Akalin, K. Berntorp, A. Ceriello, A. K. Das, E. S. Kilpatrick, T. Koblik, C. S. Munichoodappa, C. Y. Pan, W. Rosenthall, M. Shestakova, B. Wolnik, V. Woo, W. Y. Yang, M. T. Yilmaz

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There is compelling evidence showing that achieving good glycaemic control reduces the risk of microvascular complications in people with type 1 and type 2 diabetes. Likewise, there is clear evidence to show that achieving good glycaemic control reduces the risk of macrovascular complications in type 1 diabetes. The UKPDS 10-year follow up suggests that good glycaemic control also reduces the risk of macrovascular complications in type 2 diabetes. Despite this, recent results from ACCORD, ADVANCE and VADT present conflicting results and data from the ACCORD trial appear to suggest that very low HbA _1c targets (1c targets (

Original language	English
Pages (from-to)	1421-1425
Number of pages	5
Journal	International Journal of Clinical Practice
Volume	63
Issue number	10
DOIs	https://doi.org/10.1111/j.1742-1241.2009.02165.x
Publication status	Published - 2009

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1111/j.1742-1241.2009.02165.x

Cite this

Akalin, S., Berntorp, K., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C. S., Pan, C. Y., Rosenthall, W., Shestakova, M., Wolnik, B., Woo, V., Yang, W. Y., & Yilmaz, M. T. (2009). Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control. International Journal of Clinical Practice, 63(10), 1421-1425. https://doi.org/10.1111/j.1742-1241.2009.02165.x

Intensive glucose therapy and clinical implications of recent data : A consensus statement from the Global Task Force on Glycaemic Control. / Akalin, S.; Berntorp, K.; Ceriello, A.; Das, A. K.; Kilpatrick, E. S.; Koblik, T.; Munichoodappa, C. S.; Pan, C. Y.; Rosenthall, W.; Shestakova, M.; Wolnik, B.; Woo, V.; Yang, W. Y.; Yilmaz, M. T.

In: International Journal of Clinical Practice, Vol. 63, No. 10, 2009, p. 1421-1425.

Research output: Contribution to journal › Article › peer-review

Akalin, S, Berntorp, K, Ceriello, A, Das, AK, Kilpatrick, ES, Koblik, T, Munichoodappa, CS, Pan, CY, Rosenthall, W, Shestakova, M, Wolnik, B, Woo, V, Yang, WY & Yilmaz, MT 2009, 'Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control', International Journal of Clinical Practice, vol. 63, no. 10, pp. 1421-1425. https://doi.org/10.1111/j.1742-1241.2009.02165.x

Akalin, S. ; Berntorp, K. ; Ceriello, A. ; Das, A. K. ; Kilpatrick, E. S. ; Koblik, T. ; Munichoodappa, C. S. ; Pan, C. Y. ; Rosenthall, W. ; Shestakova, M. ; Wolnik, B. ; Woo, V. ; Yang, W. Y. ; Yilmaz, M. T. / Intensive glucose therapy and clinical implications of recent data : A consensus statement from the Global Task Force on Glycaemic Control. In: International Journal of Clinical Practice. 2009 ; Vol. 63, No. 10. pp. 1421-1425.

@article{baeb565aaff94c5192447d5b2fb8e5de,

title = "Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control",

abstract = "Background: There is compelling evidence showing that achieving good glycaemic control reduces the risk of microvascular complications in people with type 1 and type 2 diabetes. Likewise, there is clear evidence to show that achieving good glycaemic control reduces the risk of macrovascular complications in type 1 diabetes. The UKPDS 10-year follow up suggests that good glycaemic control also reduces the risk of macrovascular complications in type 2 diabetes. Despite this, recent results from ACCORD, ADVANCE and VADT present conflicting results and data from the ACCORD trial appear to suggest that very low HbA 1c targets (1c targets (",

author = "S. Akalin and K. Berntorp and A. Ceriello and Das, {A. K.} and Kilpatrick, {E. S.} and T. Koblik and Munichoodappa, {C. S.} and Pan, {C. Y.} and W. Rosenthall and M. Shestakova and B. Wolnik and V. Woo and Yang, {W. Y.} and Yilmaz, {M. T.}",

year = "2009",

doi = "10.1111/j.1742-1241.2009.02165.x",

language = "English",

volume = "63",

pages = "1421--1425",

journal = "International Journal of Clinical Practice",

issn = "1368-5031",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Intensive glucose therapy and clinical implications of recent data

T2 - A consensus statement from the Global Task Force on Glycaemic Control

AU - Akalin, S.

AU - Berntorp, K.

AU - Ceriello, A.

AU - Das, A. K.

AU - Kilpatrick, E. S.

AU - Koblik, T.

AU - Munichoodappa, C. S.

AU - Pan, C. Y.

AU - Rosenthall, W.

AU - Shestakova, M.

AU - Wolnik, B.

AU - Woo, V.

AU - Yang, W. Y.

AU - Yilmaz, M. T.

PY - 2009

Y1 - 2009

N2 - Background: There is compelling evidence showing that achieving good glycaemic control reduces the risk of microvascular complications in people with type 1 and type 2 diabetes. Likewise, there is clear evidence to show that achieving good glycaemic control reduces the risk of macrovascular complications in type 1 diabetes. The UKPDS 10-year follow up suggests that good glycaemic control also reduces the risk of macrovascular complications in type 2 diabetes. Despite this, recent results from ACCORD, ADVANCE and VADT present conflicting results and data from the ACCORD trial appear to suggest that very low HbA 1c targets (1c targets (

AB - Background: There is compelling evidence showing that achieving good glycaemic control reduces the risk of microvascular complications in people with type 1 and type 2 diabetes. Likewise, there is clear evidence to show that achieving good glycaemic control reduces the risk of macrovascular complications in type 1 diabetes. The UKPDS 10-year follow up suggests that good glycaemic control also reduces the risk of macrovascular complications in type 2 diabetes. Despite this, recent results from ACCORD, ADVANCE and VADT present conflicting results and data from the ACCORD trial appear to suggest that very low HbA 1c targets (1c targets (

UR - http://www.scopus.com/inward/record.url?scp=70349237376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349237376&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2009.02165.x

DO - 10.1111/j.1742-1241.2009.02165.x

M3 - Article

C2 - 19769698

AN - SCOPUS:70349237376

VL - 63

SP - 1421

EP - 1425

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 10

ER -

Intensive glucose therapy and clinical implications of recent data: A consensus statement from the Global Task Force on Glycaemic Control

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this